Liver failure

Current Opinion in Anaesthesiology

Volumn 18, Issue 2, 2005, Pages 111-116

  Bauer, Michael ^a   Winning, Johannes ^b   Kortgen, Andreas ^b  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b NONE

Author keywords

Acute; Acute on chronic; Extracorporal support; Indocyanine green; Liver transplantation

Indexed keywords

INDOCYANINE GREEN;

APOPTOSIS; ARTIFICIAL LIVER; BLOOD CLOTTING DISORDER; CARDIOMYOPATHY; CHRONIC LIVER DISEASE; HEPATIC ENCEPHALOPATHY; HEPATOPULMONARY SYNDROME; HEPATORENAL SYNDROME; HIGH RISK POPULATION; HUMAN; LIVER CELL DAMAGE; LIVER DISEASE; LIVER FAILURE; LIVER TRANSPLANTATION; PATHOPHYSIOLOGY; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; REVIEW;

EID: 17144403842     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aco.0000162827.74270.32     Document Type: Review

References (40)

1. Mullin EJ, Metcalfe MS, Maddern GJ. Artificial liver support - potential to retard regeneration. Arch Surg 2004; 139:670-677.
2. Mas A, Rodes J. Fulminant hepatic failure. Lancet 1997; 349:1081-1085.
3. Organ Procurement and Transplant Network/Scientific Registry of Transplant Recipients (OPTN/SRTR) data. 1 August 2002. www.optn.org.
4. Marrero J, Martinez FJ, Hyzy R. Advances in critical care hepatology. Am J Respir Crit Care Med 2003; 168:1421-1426.
5. Munoz SJ, Maddrey WC. Major complications of acute and chronic liver disease. Gastroenterol Clin North Am 1988; 17:265-287.
6. Sen S, Williams R, Jalan R. The pathophysiological basis of acute-on-chronic liver failure. Liver 2002; 22(Suppl 2):5-13.
7. Song TJ, Ip EW, Fong Y. Hepatocellular carcinoma: current surgical management. Gastroenterology 2004; 127:3248-3260.
8. Scatton O, Massault PP, Dousset B, et al. Major liver resection without clamping: a prospective reappraisal in the era of modern surgical tools. J Am Coll Surg 2004; 199:702-708.
9. Mandell MS, Durham J, Kumpe D, Trotter JF, Everson GT, Niemann CU. The effects of desflurane and propofol on portosystemic pressure in patients with portal hypertension. Anesth Analg 2003; 97:1573-1577.
10. Ogasawara J, Watanabe-Fukunaga R, Adachi M, et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993; 364:806-809.
11. Kon K, Kim JS, Jaeschke H, Lemasters JJ. Mitochondrial permeability transition in acetaminophen-induced necrosis and apoptosis of cultured mouse hepatocytes. Hepatology 2004; 40:1170-1179.
12. Paxian M, Bauer I, Rensing H, et al. Recovery of hepatocellular ATP and "pericentral apoptosis" after hemorrhage and resuscitation. FASEB J 2003; 17:993-1002.
13. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348:138-150.
14. Sakka SG, Reinhart K, Meier-Hellmann A. Prognostic value of the indocyanine green plasma disappearance rate in critically ill patients. Chest 2002; 122:1715-1720.
15. Erdogan D, Heijnen BH, Bennink RJ, et al. Preoperative assessment of liver function: a comparison of 99mTc-Mebrofenin scintigraphy with indocyanine green clearance test. Liver Int 2004; 24:117-123.
16. Nanashima A, Yamaguchi H, Shibasaki S, et al. Relationship between indocyanine green test and technetium-99m galactosyl serum albumin scintigraphy in patients scheduled for hepatectomy: clinical evaluation and patient outcome. Hepatol Res 2004; 28:184-190. Interesting study comparing ICG clearance and technetium-99m galactosyl serum albumin scintigraphy in 140 patients undergoing partial hepatectomy to assess hepatic functional reserve and predict clinical outcome.
17. Vaquera J, Chung C, Blei AT. Cerebral blood flow in acute liver failure: a finding in search of a mechanism. Metab Brain Dis 2004; 19:177-194. Excellent review summarizing pathophysiology of increased intracranial pressure in liver failure with special emphasis on the regulation of increases in blood flow - a significant pathogenetic factor of (late) intracranial hypertension.
18. Vaquero J, Chung C, Blei AT. Brain edema in acute liver failure. A window to the pathogenesis of hepatic encephalopathy. Ann Hepatol 2003; 2:12-22.
19. Shawcross DL, Davies NA, Mookerjee RP, et al. Worsening of cerebral hyperemia by the administration of terlipressin in acute liver failure with severe encephalopathy. Hepatology 2004; 39:471-475. In a small single-centre study the authors report that terlipressin, which might be useful in patients with acute liver failure and HRS, can worsen intracranial hypertension in patients with concomittant cerebral oedema.
20. Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996; 23:164-176.
21. Ortega R, Gines P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002; 36:941-948.
22. Heemann U, Treichel U, Loock J, et al. Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology 2002; 36:949-958.
23. Cassinello C, Moreno E, Gozalo A, et al. Effects of orthotopic liver transplantation on vasoactive systems and renal function in patients with advanced liver cirrhosis. Dig Dis Sci 2003; 48:179-186.
24. Schrier RW, Arroyo V, Bernardi M, et al. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8:1151-1157.
25. Cardenas A, Uriz J, Gines P, Arroyo V. Hepatorenal syndrome. Liver Transpl 2000; 6;S63-S71.
26. Angeli P, Volpin R, Piovan D, et al. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites. Hepatology 1998; 28:937-943.
27. Bachmann-Brandt S, Bittner I, Neuhaus P, et al. Plasma levels of endothelin-1 in patients with the hepatorenal syndrome after successful liver transplantation. Transpl Int 2000; 13:357-362.
28. Duvoux C, Zanditenas D, Hezode C, et al. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology 2002; 36:374-380.
29. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004; 40:55-64. Clinical study addressing sequential treatment of patients with HRS using vasopressors followed if required by TIPS. In addition to clinical insights the study sheds light on the pathogenesis of HRS.
30. Gines P, Uriz J, Calahorra B, et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002; 123:1839-1847.
31. Mitzner SR, Stange J, Klammt S, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis. MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000; 6:277-286.
32. Mitzner SR, Klammt S, Peszynski P, et al. Improvement of multiple organ functions in hepatorenal syndrome during albumin dialysis with the molecular adsorbent recirculating system. Ther Apher 2001; 5:417-422.
33. Lee SS. Cardiac dysfunction in spontaneous bacterial peritonitis: a manifestation of cirrhotic cardiomyopathy? Hepatology 2003; 38:1089-1091.
34. Abrams GA, Fallon MB. The hepatopulmonary syndrome. Clin Liver Dis 1997; 1:185-200.
35. Caldwell SH, Chang C, Macik BG. Recombinant activated factor VII (rFVIIa) as a hemostatic agent in liver disease: a break from convention in need of controlled trials. Hepatology 2004; 39:592-598. Excellent overview of potential use of rVIIa to correct bleeding disorders and allow invasive measures with special emphasis on risk-benefit ratioand cost-effectiveness.
36. Bauer M. Heme oxygenase in liver transplantation: heme catabolism and metabolites in the search of function. Hepatology 2003; 38:286-288.
37. Selden C, Hodgson H. Cellular therapies for liver replacement. Transpl Immunol 2004; 12:273-288. Overview of current state of in-vitro tissue engineering to allow orthotopic or heterotopic isolated liver cell transplantation and development of a bioartificial extracorporeal hepatic support system.
38. Khuroo MS, Khuroo MS, Farahat KL. Molecular adsorbent recirculating system for acute and acute-on-chronic liver failure: a meta-analysis. Liver Transpl 2004; 10:1099-1106. Systematic review confirming the dilemma that, although thousands of patients have been treated with MARS worldwide, no sufficiently powered studies have been conducted so far to identify those patients likely to benefit from this resource-consuming therapy.
39. ..] by a potential false negative result in the light of small numbers of patients and poor data quality in the source studies.
40. Demetriou AA, Brown RS, Busuttil RW, et al. Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg 2004; 239:660-670. First randomized controlled trial on the use of a bioartificial liver support system in patients with acute liver failure. Although a total of 171 patients were randomized, the power is marginal and significance is reached for a subgroup of patients only.